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Proximal nephron and renal effects of DuP 753, a nonpeptide angio.
tensin II receptor antagonist. The purpose of these studies was to
quantitatively assess the role of endogenous angiotensin II activity in
controlling transport in the proximal convoluted tubule (PCT) and
whole nephron. We used the nonpeptide an8iotensin II receptor antag-
onist DuP 753, which lacks the agonist and kinin/prostaglandin-inducing
properties of saralasin and captopril, respectively. During in vivo
microperfusion in the Munich-Wistar rat, we found that DuP 753 had a
powerful inhibitory effect on bicarbonate (370 3 to 200 9 pEq/mm
mm, P < 0.001), chloride (214 3 to 105 9 pEq/mm mm, P <
0.001), and water (5.2 0.1 to 2.8 0.2 nI/mm mm, P < 0.001)
absorption in the Si subsegment of the PCT. At maximally effective
doses, DuP 753 (10 mg/kg i.v.) was significantly more effective than was
captopril (3 mg/kg i.v.) in inhibiting sodium chloride transport in the SI
PCT. DuP 753 is the most potent diuretic ever described in this
segment. Consistent with the axial decline of angiotensin II receptor
density in the PCT, DuP 753 was a less effective transport inhibitor in
the S2 subsegment of the PCT, similar to captopril. Though down-
stream reabsorptive elements partially compensate for the action in the
earliest segment of the nephron, we also showed using free-flow
micropuncture and clearance techniques that DuP 753 induces a sub-
stantial diuresis, natriuresis and chloruresis. In conclusion, the marked
decrease in SI PCT fluid and electrolyte absorption induced by DuP 753
indicates that endogenous angiotensin II exerts significant tonic support
of proximal transport in vivo.
Increasing evidence suggests that angiotensin II controls
renal sodium excretion not only by affecting renal hemodynam-
ics and aldosterone biosynthesis but also by directly regulating
epithelial sodium transport [1—3]. Recently, we have character-
ized the nephron site, solute-specificity, and mechanism of this
process. Angiotensin II acts predominantly in the Si subseg-
ment of the proximal convoluted tubule (PCT) to reduce intra-
cellular cAMP and hence increase Na/H antiporter activity
[4-6].
Probing the quantitative significance of this transport-regula-
tory system under physiologic and pathophysiologic circum-
stances requires an agent which selectively and potently inhib-
its the action of angiotensin II. Unfortunately, currently
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available pharmacologic tools for interrupting the activity of
angiotensin II are imperfect. Saralasin has partial agonistic
activity while converting enzyme inhibitors increase kinin and
prostaglandin levels concomitant with reduction in angiotensin
II level [7].
Nonpeptide molecules such as DuP 753 have been recently
described which specifically and competitively block angioten-
sin II binding to its receptor [8—il]. DuP 753 lacks agonistic or
kinin- and prostaglandin-inducing properties [10, 11]. Such an
antagonist affords a unique opportunity to quantitate the role of
endogenous angiotensin II on PCT and renal sodium transport.
In the present studies, we first confirmed that intravenous
administration of 10 mg/kg DuP 753 could maximally antagonize
the action of angiotensin II, and had a sufficiently long duration
of action to be useful for assessing changes in transport using
micropuncture techniques. Using in vivo microperfusion, we
next ascertained the effect of DuP 753 on sodium, bicarbonate,
and chloride transport in both the Sl and S2 PCI. Finally, we
used free-flow micropuncture techniques to examine the inte-
grated effects of DuP 753 on segmental nephron and whole
kidney fluid and electrolyte transport. Comparison was made of
DuP 753 to a maximally effective dose of captoprml on the same
transport parameters.
Methods
Studies on the efficacy and duration of angiotensin II
antagonism by DuP 753 and captopril
Three hundred and thirty to 350 g male CD Sprague-Dawley
rats (Charles River Laboratories, Kingston, New York, USA)
were anesthetized with mactin (110 mg/kg i.p.). The trachea,
right jugular vein and carotid artery were cannulated. Systemic
blood pressure was monitored via the carotid artery using a
pressure transducer (Gould Inc., Oxnard, California, USA) and
recorded on a polygraph (Grass Instrument Co, Quincy, Mas-
sachusetts, USA).
In the first series of experiments, we assessed the duration of
angiotensin II antagonism following intravenous administratiOn
of DuP 753 (2-n-butyl-4-chloro-5-hydroxymethyl-i-[(2'-( 1H-tet-
razol-5-yl)biphenyl-4-yl)methyl] imidazole, potassium salt, syn-
thesized by E. I. Du Pont de Nemours & Co., Wilmington)
[8—li]. Angiotensin II was injected at 0.1 p.g/kg i.v., prior to the
administration of saline vehicle 1 ml/kg i.v. (N = 6) or DuP 753
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10 mg/kg i.v. (N = 6), and subsequently at S to 30 minute
intervals for 90 minutes post-dose. In the second series of
experiments, the duration of angiotensin I antagonism following
intravenous administration of captopril (synthesized by E. I. Du
Pont de Nemours & Co.) was studied. Angiotensin I was
injected at 0.3 pg/kg i.v., prior to the administration of saline
vehicle 1 ml/kg i.v. (N = 6) or captopril 3 mg/kg i.v. (N = 6),
and subsequently at 5 to 30 minute intervals for 90 minutes
post-dose. A 90 minute observation period was chosen since the
microperfusion and micropuncture measurements were made
within this time interval following drug administration.
The doses of DuP 753 (10 mg/kg) and captopril (3 mg/kg) had
been chosen on the basis of preliminary experiments of dose-
response relationships showing that they provided maximal
antagonism of the pressor responses to angiotensin II and I,
respectively. In these preliminary studies, DuP 753 (N = 5) or
captopril (N = 5) was given in graded doses, 0,0.3, 1, 3, and 10
mg/kg or 0, 0.1, 0.3, 1 and 3 mg/kg, respectively, in a cumulative
manner at intervals of 15 minutes. The pressor response to
angiotensin II (DuP 753) or angiotensin I (captopril) administra-
tion was assessed before drug infusion and subsequently five
minutes after each successive DuP 753 or captopril dose. The
pressor responses to increasing dose of DuP 753 were 31
2, 2 and 5 1 mm Hg, and to increasing dose
of captopril were 39 3, 11 2,7 1,5 2 and4 1mm Hg.
Thus, DuP 753 and captopril significantly inhibited the pressor
response at 3 mg/kg and 0.1 mg/kg, respectively, and achieved
maximal responses at 10 mg/kg and 1 and 3 mg/kg, respectively.
Preparation of animals for microperfusion or micropuncture
Two hundred to 220 g male Munich-Wistar rats (Simonsen
Laboratories, Gilroy, California, USA) were fed a nutritionally
complete diet with free access to water, as previously described
[4—6, 12—15]. Anesthetic preparation for microperfusion or
micropuncture was effected with mactin (100 to 110 mg/kg i.p.).
A tracheostomy was performed and the rat was placed on a
heated table to maintain body temperature at 37°C. The left
femoral artery, both jugular veins and the ureter were catheter-
ized. A vehicle infusion of bicarbonate Ringer's solution was
begun at 1.2 mI/hr.
Microperfusion technique
The techniques for in vivo microperfusion of paired early and
late portions of the same PCT were used as previously reported
from this laboratory [4-6, 14]. The left kidney was exposed by
flank incision, and then immobilized in a lucite holder. The
surface of the kidney was bathed with mineral oil that was
water-equilibrated, bubbled with 95% 02/5% C02, and heated
to 37°C.
A small oil droplet was injected into Bowman's space and the
entire PCT mapped. The late portion of the PCT, the S2
subsegment, defined as being 2.0 to 2.5 mm from the glomeru-
lus, was first studied. The microperfusion pipette was placed in
the lumen at the beginning of this segment for orthograde
perfusion. A thermally insulated microperfusion pump (Wolf-
gang Hampel, Berlin, FRG) set at 30 nI/mm was utilized. The
basic ultrafiltrate-like perfusion solution contained (in mM):
NaC1 120; NaHCO3 25; KCI5; MgSO4 1; CaCI2 1.8; Na2PO4 1;
glucose 5; alanine 5; and urea 5; gassed with 93% 02/7% CO2
and containing 0.1% FD and C green dye no.3 and exhaustively
dialyzed [3H-methoxy}-inulin. A red-stained oil block was then
placed proximal to the perfusion pipette and a hole left for
endogenous tubular fluid to leak out. The collection pipette was
placed in the end-proximal ioop, a stained, HEPES/10% CO2
equilibrated paraffin oil block inserted and maintained distally,
and a timed (3 to 4 mm) collection made.
The early PCT of the same nephron was then studied. Since
the Si segment is shorter (1 to 2 mm), the length perfused for
early PCT measurements was less (about 1 mm or I to 2 surface
loops) than for the late PCT. In general, the same procedures
for perfusion and collection were used as in the late PCT. To
ensure easy escape of glomerular ultrafiltrate, one to two holes
were made in Bowman's space before perfusion. The oil block
was inserted at the junction of Bowman's space and the
beginning of the PCT after the perfusion pipette is inserted into
the lumen about 0.1 to 0.2 mm from Bowman's space.
DuP 753 (10 mg/kg i.v., N = 5) or captopril (3 mg/kg i.v., N
= 5) was then added to the vehicle infusion. Both doses were
established in preliminary studies to be maximally effective in
inhibiting PCT transport. After an equilibration period of 45 to
60 minutes, the measurements described above were repeated.
To measure tubule length, after five hours to allow the tubule
puncture sites to seal, Microfil (Canton Biomedical Products,
Boulder, Colorado, USA) was injected into the perfused seg-
ments. At a later time, the kidney was incubated for 30 to 40
minutes in 6 N HCI. The cast of the tubule was dissected, with
puncture sites identified, and photographed to measure micro-
perfused segment lengths.
Free-flow micropuncture technique
This technique was used as previously described [12, 13, 15].
After anesthesia and preparation as above, the abdomen was
opened by a midline incision and the kidney stabilized and
bathed in warmed mineral oil (37°C). To restore euvolemia and
correct the plasma volume contraction incurred by the micro-
puncture preparatory surgery, an isoncotic plasma infusion was
employed, as described previously in our laboratory [12, 13,
15]. Isoncotic plasma was obtained from donor sibling rats
maintained identically to the rat under study, given as an
infusion of 1.3% body weight over 20 to 30 minutes and then as
a sustaining infusion of 5 d/min to maintain a normal plasma
volume, SNGFR, GFR, and urinary NaCI excretion rate.
Following an equilibration time of  one hour, timed three to
eight minute collections were obtained from Bowman's space,
the end-proximal tubule, and the early distal tubule using 7 to 9
pm OD glass pipettes. Coinciding with the micropuncture
measurements, whole kidney solute and water clearances were
measured using two or three 15-minute clearance periods.
All measurements were repeated (using fresh tubules for the
micropuncture sampling) following DuP 753 (N = 6) or capto-
pril (N = 6) administration as above.
Analysis and calculations
After volume of collected tubule fluid was measured, aliquots
were taken to measure inulin by scintillation counting, total
CO2 by microcalorimetry, and chloride by the Ramsay microti-
trimetric method, as previously described in our laboratory
[4—6, 12—151. Plasma and urine electrolytes were measured by
standard flame photometry and coulometric means. SNGFR,
GFR, and transport and delivery rates were calculated by
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Table 1. Effects of DuP 753 and captopnl on water, bicarbonate and chloride absorption during micrope
proximal convoluted tubule of the Munich-Wistar rat
rfusion of the early (S1) and late (S2)
Perfusion
[HCO3]
Perfusion Perfusion Collected Collected Collected[Cl] rate [HCO3] [Cl] rate
m nI/mm mi ni/mm J,nI/mm/mm
HCO3 CI
pEq/mm/mmnGroup
Early SIPCT
Control (N = 5) 24.2 0.2 119.0 0.1 29.9 0.1 16,9 0.3 130.9 1.7 25.8 0.2 5.2 0.1 370 3 214 3
DuP 753 29.8 0.1 20.5 0.3 125.5 0.3 27.6 0.1 2.8 0.2 200 9 105 9
P < NS 0.001 0.005 0.001 0.001 0.001 0.001
Control (N = 5) 24.5 0.2 119.1 0.1 29.8 0.1 16.9 0.1 131.8 0.7 25.5 0.2 5.3 0.1 373 3 222 6
Captopril 29.9 0.1 20.7 0.3 127.1 1.1 27.2 0.2 3.4 0.3 211 11 132 7
P < NS 0.001 0.005 0.001 0.001 0.001 0.001
p <a NS NS 0.05
Late S2 PCT
Control (N = 5) 24.2 0.2 119.0 0.1 29.9 0.1 9.4 0,2 123,2 1.3 25.1 0.3 2.1 0.1 210 3 202 2
DuP 753 29.9 0.1 11.2 0.3 122.1 0.8 26.9 0.3 1.3 0.1 182 3 132 7
P< NS 0.001 0.005 0.001 0.001 0.001 0.001
Control (N = 5) 24.5 0.2 119.1 0.1 29.8 0.1 9.6 0.2 121.6 1.3 25.5 0.3 1.9 0.1 211 2 202 2
Captopril 29.9 0.1 11.1 0.3 119.4 1.4 27.2 0.4 1.1 0.2 187 3 136 4
P< NS 0.001 0.005 0.001 0.001 0.001 0.001
p<a NS NS NS
a Difference of responses to DuP 753 vs. captopril (AJ vs. iJ)
standard formulae. Data are expressed as mean SEM. Signif-
icance was assessed using the paired (-test for results obtained
in the same tubule/animal or the unpaired t-test for results in
different tubules/animals.
Results
Duration and efficacy of DuP 753 and captopril on inhibition
of angiotensin II activity
As shown in Figure 1A, the pressor response to angiotensin II
was abolished following DuP 753 10 mg/kg i.v. for the full 90
minutes of observation. Similarly, as shown in Figure 1B, the
pressor response to angiotensin I was similarly lost for 90
minutes following captopril 3 mg/kg.
Effect of DuP 753 on fluid and electrolyte transport in the Si
and 52 PCT of the rat as evaluated by in vivo microperfusion
S 1 and S2 subsegments of the same PCT were microperfused
in vivo before and after DuP 753 (10 mg/kg i.v.) or captopril (3
mg/kg Lv.). These doses were shown in preliminary studies to
yield maximal physiologic inhibition with respect to both sys-
temic blood pressure response to pressor infusion (see above)
and PCT transport (data not shown). As shown in Table 1 and
Figure 2, in the Si PCT, DuP 753 caused a 46% reduction in
bicarbonate absorption (370 3 to 200 9 pEq/mm mm, P <
0.001) and a 51% reduction in chloride absorption (214 3 to
105 9 pEq/mm mm, P < 0.001), resulting in a 46% reduction
in sodium and water absorption (5.2 0.1 to 2.8 0.2
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Fig. 1. A. The increment in blood pressure over baseline in response to angiotensin II infusion (at 0 mm and subsequent 5 to 30 mm intervals)
following treatment (arrow) with either vehicle (0) or DuP 753 10 mg/kg i.v. (•) in normotensive rats. B. The increment in blood pressure over
baseline in response to angiotensin I infusion (at 0 mm and subsequent 5 o 30 mm intervals) following treatment at 0 mm (arrow) with either vehicle
(0) or captopril 3 mg/kg i.v. (•) in normotensive rats.
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DuP 753 inhibits Si PCT chloride transport more powerfully
than captopril.
Effect of DuP 753 on fluid and electrolyte reabsorption in the
proximal and distal tubules and whole rat kidney under free-
flow conditions as evaluated by micropuncture and clearance
techniques
$1I
nllmm mm, P <0.001). When compared to captopril, DuP 753
exerted a more profound inhibitory effect on chloride absorp-
tion (P < 0.05).
In the S2 PCT, there are tenfold less angiotensin II receptors
and substantially reduced physiologic response to angiotensin
II compared to the Sl PCT [4, 5]. Thus, the potency of DuP 753
was expected to be somewhat less in the S2 than in the 51 PCT.
As shown in Table 1, DuP 753 reduced bicarbonate absorption
by 13% (210 3 to 182 3 pEq/mm mm, P < 0.001), chloride
absorption by 35% (202 2 to 132 7 pEq/mm mm, P <
0.001), and sodium and water absorption by 42% (2.1 0.1 to
1.3 0.1 nl/mm mm, P <0.001). The inhibitory effects of DuP
753 were comparable to those of captopril in the S2 PCT.
In summary, DuP 753 hasa potent inhibitory effect on sodium
bicarbonate and sodium chloride absorption in the Si PCT in
vivo. The absolute and fractional responses were greater in the
Si compared to the S2 PCT, consistent with the known high
density of angiotensin II receptors in the initial subsegment [5].
Free-flow sampling of Bowman's space, the end-PCT, and
the early distal tubule were obtained simultaneously with whole
kidney clearance measurements before and after DuP 753 (10
mg/kg i.v.) or captopril (3 mg/kg i.v.). As shown in Table 2,
measurements of SNGFR were comparable in the three sites of
measurement and showed a substantial increase following DuP
753 of 21% (averaging 34.7 2.1 to 42.1 2.7 nl/min, P <
0.001). In response to the increased filtered load, absolute
proximal reabsorption (APR) of bicarbonate, chloride and wa-
ter increased by 109 pEq/min (799 46 to 908 58 pEq/min, P
<0.005), 54 pEq/min (1351 89 to 1405 102 pEq/min, NS),
and 3.1 nI/mm (17.9 1.0 to 21.0 1.2 nl/min, P < 0.002),
respectively, but these increments were substantially less than
the normal physiologic load-dependent responses expected (358
pEq/min, 512 pEq/min, and 6.6 nI/mm, respectively, when a
comparable change in SNGFR occurs during transition from
hydropenia to euvolemia [13]) due to direct inhibition of trans-
port exerted by DuP 753. We have previously found that
transport stimulation induced by an increase in flow rate can at
least partially overcome the inhibition of transport directly
effected by angiotensin II blockade [5]. As shown in Figure 3,
the result of these glomerulo-tubular dynamics induced by
angiotensin II antagonism was a marked increase in delivery out
of the superficial PCT to the distal nephron of bicarbonate,
chloride, and sodium and water, rising over baseline values by
75%, 32%, and 25%, respectively.
Absolute fluid and electrolyte absorption in the ioop in-
creased, but not proportional to the increment in load. Hence,
as shown in Table 2 and Figure 3, delivery out solute and water
out of the superficial distal convoluted tubule increased by 50 to
100%: bicarbonate 40 6 to 81 7 pEq/mmn (P < 0.005),
chloride 307 22 to 529 45 pEq/min (P < 0.01), and water 7.6
0.6 to 10.6 0.5 nI/mm (P <0.02).
Concomitant with the enhanced solute and water delivery out
of the distal tubule, there was a two- and fourfold increase in
urinary excretion of water (2.1 0.3 to 4.9 1.0 jsllmin),
sodium (263 60 to 995 481 nEq/min, P < 0.01), and chloride
(375 73 to 704 119 nEqlmmn, P < 0.01). Only minor
substantive differences in single nephron and in whole kidney
effects were observed between DuP 753 and captopril, though
the chloruresis was significantly greater with DuP 753. The
greater chloruretic effect without significant difference in end-
proximal or early distal chloride delivery rates suggest DuP 753
may have additional actions in the collecting tubule and/or
juxtamedullary nephron.
In summary, DuP 753 has substantial diuretic, natriuretic and
chloruretic potency. The mechanism of the effect is due, at least
in part, to its ability to increase glomerular filtration while
simultaneously inhibiting transport in the PCT and possibly in
the distal nephron.
250 -
200
150
100 -
o 50
5.00
C
.c 3.750.0.
. E 2.50
1.25
Fig. 2. Bicarbonate (A), chloride (B), and water (C) absorption during
in vivo microperfusion of the rat early (Si) PCT in the presence of
vehicle (D, combined control periods of both drugs), captopril 3 mg/kg
i.v. (a), orDuP 753 10mg/kg i.v. (G). * P <0.001 control vs. captopril
or DuP 753. t P < 0.05 captopril vs. DuP 753.
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Table 2. Effects of DuP 753 and captopril on water, bicarbonate, and chloride reabsorption during free-flow micropuncture of proximal and
distal tubules with simultaneous whole kidney clearances in the Munich-Wistar rat
Group
SNGF
Filtered Filtered
R nI/mm BS mM HCO3 Cl
N BS End-prox Distal Avg [HCO3] [Cl] pEq/min
Control 6 35.4 2.2 34.7 2.0 34.1 2.1 34.7 2.1 27.0 0.5 101.6 0.9 949 49 3602 233
DuP 753 42.7 2.9 42.3 2.9 41.5 2.5 42.1 2.7 27.3 1.0 101.2 0.7 1159 68 4327 306
P< 0.002 0.002 0.001 0.001 NS NS 0.005 0.002
Control 6 34.6 1.6 33.0 1.7 33.3 1.4 34.0 1.6 26.1 0.9 101,5 0.9 911 72 3522 133
Captopril 42.6 2.7 41.9 2.6 41.4 2.6 42.0 2.6 26.4 1.1 101.4 0.9 1133 112 4318 251
P< 0.005 0.002 0.002 0.001 NS NS 0.005 0.005
p<a NS NS NS NS NS NS NS NS
End-PCT Distal APR
[HCO3] [Cl] V [HCO3] [Cl] HCO3 Cl H20
Group nI/mm mM mM nI/mm mM mM pEq/min pEqimin ni/mm
Control 16.9 1.1 8.2 0.6 129.2 0.4 7.6 0.6 5.3 0.6 40.6 0.8 799 46 1351 89 17.9 1.0
DuP 753 21.2 1.7 11.4 1.0 135.5 1.7 10.6 0.5 7.6 0.5 49.8 2.7 908 58 1405 102 21.0 1.2
P< 0.005 0.005 NS 0.02 0.01 0.01 0.005 NS 0.002
Control 16.5 1.1 9.3 0.8 129.3 0.6 7,5 0.7 5.8 1.0 42.0 0.8 738 69 1312 44 17.5 0.7
Captopril 21.5 1.8 10.4 0.9 140.5 1.0 9.9 1.8 7.3 1.4 55.1 1.7 889 97 1230 51 20.4 0.9P< 0.01 0.05 0.001 0.001 NS 0.001 0.005 NS 0.002
p<a NS 0.02 0.05 NS NS NS NS NS NS
ADR End-PCT delivery Distal delivery
HCO3 Cl H20 HCO3 Cl HCO3 Cl
Group pEqimin pEq/mmn ni/mm pEqlmmn pEqimin pEq/min pEq/min
Control 867 48 3154 237 26.4 2.2 135 6 2183 153 40 6 307 22
DuP 753 1046 60 3678 259 31.2 2.4 238 21 2874 230 81 7 529 45
P< 0.005 0.002 0.01 0.002 0.005 0.005 0.01
Control 829 70 3059 100 25.8 1.0 153 15 2130 127 44 9 318 34
Captopril 1001 76 3649 208 31.5 2.0 221 23 3012 243 71 15 544 47
P< 0.01 0.005 0.01 0.01 0.05 0.05 0.001
p<a NS NS NS NS NS NS NS
Group
GFR V
mi/mm
.d/min
UNaV UKV U1V UHc03V
(nEqimmn)
Control 1.9 0.1 2.1 0.3 263 60 145 20 375 73 9 5
DuP 753 2.0 0.1 4.9 1.0 995 481 390 112 704 119 53 20
P< NS 0.02 0.06 NS 0.01 0.05
Control 1.5 0.2 2.0 0.3 461 165 139 25 262 100 3 1
Captopril 1.6 0.2 3.0 0.4 778 206 201 32 354 79 25 10P< NS 0.02 0.02 0.06 NS NS
p.<a NS NS NS NS 0.02 NS
Abbreviations are: BS, Bowman's space; APR, absolute proximal reabsorption; ADR, absolute distal (proximal + loop) reabsorption; V, flow
rate
a Difference of responses to DuP 753 vs. captopril (va1ue vs. zvalue)
Discussion
The greater inhibition of sodium, bicarbonate and chloride
transport in the Si compared to the S2 PCT by DuP 753 is
consistent with the known higher angiotensin receptor density
in the initial proximal subsegment [5]. The Si PCT transports
solute and water at a higher rate than any other nephron
segment and accounts for approximately 25% of sodium reab-
sorption in the kidney [13, 15]. Since DuP 753 suppresses about
half of Si PCT transport (Fig. 2), these results suggest that
endogenous angiotensin II activity, at least under the conditions
of these studies, has a large role in the tonic support of PCT
function.
Both saralasin and converting enzyme inhibitors were previ-
ously known to induce a natriuresis in normal animals and man
[15—191. The specific nephron site of action of these agents was
less well established. Inhibition of sodium transport in the
whole PCT has been reported for both saralasin and captopril
[4, 19—21], though no effect of these agents has been found
under some conditions [20, 22]. The mechanism of change in
renal epithelial cell transport using saralasin and converting
enzyme inhibitors is difficult to evaluate since they possess
partial agonistic properties or the confounding ability to alter
kinin and prostaglandin production, respectively. Employing
the specific angiotensin receptor antagonist DuP 753, which has
no agonist or kinin/prostaglandin-stimulating effects, the
present microperfusion and free-flow micropuncture studies
establish that the Si PCT is a nephron site affected when
endogenous angiotensin Ii is inhibited (Fig. 2) and may be at
least partially responsible for the natriuresis, chloruresis and
diuresis that simultaneously occurs (Fig. 3). Given its ability to
potently suppress the high-capacity transport processes in the
Si PCT, DuP 753 must be currently regarded as quantitatively
the most powerful inhibitor of sodium transport at the level of
the renal epithelial cell in vivo. DuP 753 is modestly, but
significantly, more effective than captopril in inhibiting S 1 PCT
as well as renal chloride transport (Figs. 2 and 3), though the
reason and the physiologic consequence for the differential
response was not established. It is possible that the difference
may be due to non-angiotensin-related effects of captopril or
better relative access of DuP 753 to its respective target protein.
The greater chloruretic potency by DuP 753 despite similar
end-proximal and early distal chloride delivery rates suggests
DuP 753 may also have inhibitory effects on collecting tubule
and/or juxtamedullary nephron chloride transport.
The reduction by DuP 753 of PCT transport in the free-flow
studies appeared to be qualitatively less than observed using in
vivo microperfusion. However, DuP 753 attenuated the normal
load-dependent increase in solute and water transport that
should have occurred due to the rise in SNGFR [12, 13, 15]. The
apparent quantitative discrepancy between the microperfusion
and free-flow studies might be explained by the fact that both
luminal flow rate and angiotensin II have the same kinetic
effects on Si PCT bicarbonate absorption, to augment the
apparent substrate affinity (that is, decrease the apparent Km) of
the transport process [5, 14]. The propensity for DuP 753 to
increase luminal flow under free-flow conditions therefore mit-
igates its degree of transport inhibition otherwise observed
when flow rate is rigidly controlled using microperfusion [5].
Since local angiotensin II concentration cannot be measured, it
is also possible that the two experimental techniques were
associated with different angiotensin II concentrations in con-
tiguity with the Si PCT cell.
Caution should be exercised in interpretation or extrapolation
of many aspects of these data. First, the effects of angiotensin
II have been over-simplified in the above discussion as being
restricted to Sl PCT cell receptor-mediated alteration in hydro-
gen ion secretion. Actually, there are lesser, but demonstrable,
changes elicited in S2 PCT acidification by angiotensin II, in
addition to neurally-mediated changes in sodium chloride trans-
port in both the Sl and S2 PCT [4, 5]. Second, although
previous studies using saralasin to block angiotensin II activity
showed no effect on the peritubular Starling forces [19], we did
not directly measure the peritubular protein concentration,
which can affect transcellular chloride (but not bicarbonate)
transport [23]. Third, though there was reasonable correlation
of changes in anion delivery and flow rates in PCT, distal
convoluted tubule, and urine, it should not be assumed that
solute and water delivery rates out of the superficial nephron
were causally responsible for the observed excretory patterns
by the whole kidney. Multiple factors affect urinary solute
excretion beside superficial nephron solute delivery, including
collecting duct transport, juxtamedullary nephron transport,
and medullary hemodynamics, all of which are probably af-
fected when angiotensin II is inhibited [1—3]. Fourth, undefined
in these studies was the relative importance of the luminal
versus peritubular angiotensin II receptor-signal transduction
systems [5], both of which would be blocked by DuP 753 under
free-flow conditions, or the source of angiotensin II, whether
derived from the circulation or the PCT cell itself [1]. Finally, as
with any pharmacologic study, one must be circumspect about
the specificity of DuP 753 for angiotensin II antagonism [9—11]
and consider the possibility that other, as yet undefined, mech-
anisms account for the inhibitory effect of this agent on tubular
transport.
*
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Fig. 3. Free-flow single nephron and whole
kidney delivery rates of bicarbonate (A),
chloride (B), and water (C) in the presence of
vehicle (Li, combined control periods of both
drugs), captopril 3 mg/kg i.v. (a), or DuP 753
at 3 mg/kg i.v. (0). * P < 0.05 control vs.
captopril or DuP 753. t P < 0.05 captopril vs.
DuP 753.
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Given these caveats, the effects of DuP 753 suggest that
angiotensin II's ability to coordinately regulate both glomerular
and tubular function may have significant implications for the
physiologic feedback system by which proximal sodium han-
dling participates in the efferent limb of extracellular volume
control. From a therapeutic perspective, the orally available
form of DuP 753 may also have potential utility. The ability to
simultaneously reduce blood pressure [10, 11] while augmenting
glomerular function and inhibiting renal sodium transport pre-
dicts that DuP 753 might be utilized as a sole agent in treating
hypertension, obviating the salt-retaining response of the kid-
ney that normally ensues when renal perfusion pressure is
lowered. Finally, the renal site of action of DuP 753, on the
earliest nephron segment, suggests that this agent may be
additive to, or even synergistic with, conventional diuretics
which selectively act at downstream sites.
In conclusion, these studies in which DuP 753 markedly
inhibit solute and water absorption in the Si PCT signify that
endogenous angiotensin II activity exerts significant tonic sup-
port of proximal transport in vivo.
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